Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Indaptus Therapeutics, Inc. (INDP)
Company Research
Source: GlobeNewswire
NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces it has entered into a $6 million securities purchase agreement with investor, David E. Lazar, for the purchase of non-voting convertible preferred stock of the Company. Mr. Lazar has been appointed Indaptus’ Co-Chief Executive Officer and Chairman of the Board. Jeffrey Meckler will continue as Co-CEO and remain on the Board. "In making this significant investment in Indaptus, I look forward to continuing to evaluate the Company’s lead product candidate while actively exploring strategic opportunities to drive value for our stockholders," said Mr. Lazar. "I appreciate the Board's unanimous support for this transaction and faith in my ability and proven track record to build upon the Company’s foundation and introduce new strategic alternati
Show less
Read more
Impact Snapshot
Event Time:
INDP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INDP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INDP alerts
High impacting Indaptus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INDP
News
- Indaptus Therapeutics (NASDAQ:INDP) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=INDP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source SummitGlobeNewswire
- Indaptus Therapeutics GAAP EPS of -$2.98 [Seeking Alpha]Seeking Alpha
- Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
INDP
Sec Filings
- 1/12/26 - Form 3
- 1/8/26 - Form 8-K
- 1/8/26 - Form PRE
- INDP's page on the SEC website